School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Alkermes Plc ALKS

Healthcare · Biotechnology

$40.26last close 2026-10-12 · market cap $6.75B · delayed data

Trailing returns

1M-13.57%
3M-23.40%
6M+17.72%
1Y+23.50%
5Y+26.37%

Basis: Adjusted daily closes.

What it does

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Open ALKS in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies